New Drug with Market of 400 Million Patients, Potential ROI 10-20X
I am the Chairman and CEO of a biopharmaceutical company developing a new drug that will revolutionize the treatment of patients with chronic hepatitis B. There are 400 million patients with chronic hepatitis B in the world. Current therapies rarely achieve a cure. Our drug allows the re-establishment of a proper immune response to the infection and will result in a high proportion of patients achieving long term control over their infection without the need for continuous therapy. The efficacy and safety of our drug has already been successfully demonstrated in ongoing human clinical trials. We are looking to raise funds to increase the number of patients being tested in our clinical trial. Our goal is to demonstrate that our drug is safe and effective in a larger number of patients and then to be acquired by a large pharmaceutical company. Four of the top 10 pharmaceutical companies have initiated the process of due diligence because of their interest in acquiring our technology. Companies from Japan and South Korea are also showing interests in licensing our technology. Based on the valuation projected by an expert independent American firm, new investors could expect to make a 10–20 X return over their investment. Management believes there is a high probability that an acquisition could occur over the next 3 to 18 months. Our technology is protected by worldwide patents until 2033.
We are looking for accredited investors that can invest between $50,000 and $1M CAD with the goal of raising a total of $1M. If you have an interest in learning more about this opportunity, please do not hesitate to contact me. I can provide you with more information and send you additional documentation upon request.